TUESDAY, April 12, 2016 — Use of the word “breakthrough” in the U.S. Food and Drug Administration’s expedited approval process could mislead doctors about the new drugs’ actual benefits, researchers warn. The U.S. Congress in 2012 gave FDA the power to designate a drug as a “breakthrough therapy” if preliminary ... Read More »